Sponsor study identifier
observational
500
1 country
1
Study Start
November 20, 2025
Actual (reported)Primary Completion
August 15, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
August 15, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
To prospectively investigate and integrate radiomic and immunologic signatures in patients with nasopharyngeal carcinoma (NPC) treated with either proton or photon radiotherapy, with the aim of identifying biomarkers associated with treatment response, toxicity, and long-term outcomes.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 15, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 14, 2025
Actual (reported)November 18, 2025
Actual (reported)November 20, 2025
Actual (reported)August 15, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
August 15, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Overall survival
Overall survival is defined as the time from signing the informed consent to death from any cause.
2 years
Progression free survival
2 years
Time to progression
2 years
Incidence and severity of adverse events
Proton chemoradiotherapy: 69.96 cobalt Gray equivalent (CGE) in 33 fractions
Photon chemoradiotherapy: 69.96 Gy in 33 fractions
Concurrent chemoradiotherapy will be delivered using intensity modulated proton therapy, with a total dose of 69.96 CGE administered in 33 fractions.
Concurrent chemoradiotherapy will be delivered using photon-based volumetric modulated arc therapy, with a total dose of 69.96 Gy administered in 33 fractions.
Patients with AJCC 9th edition stage I-III nasopharyngeal carcinoma undergoing definitive chemoradiotherapy using either proton or photon radiotherapy.
Chang Gung Memorial Hospital at Linkou
Taoyuan City, Taiwan, 333, Taiwan
Peripheral blood samples (including plasma and cellular components) will be collected at baseline, 6-8 weeks, and 3-4 months after the initiation of radiotherapy.
Rodney Cheng En Hsieh, MD, PhD
Chang Gung Memorial Hospital
First Submitted
November 14, 2025
First Posted
November 18, 2025
Study Start
November 20, 2025
Actual (reported)Primary Completion
August 15, 2031
Estimated5 years
Changes of myeloid-derived suppressor cell levels
4 months
Changes in MRI radiomic parameters
4 months
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
August 15, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
November 24, 2025
Record last verified: 2025-11
The sharing of individual participant data (IPD) will be conducted only after obtaining approval from the Institutional Review Board (IRB) and in accordance with applicable ethical and data protection regulations.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: